AIM: To evaluate the prognostic factors of ovarian granulosa cell tumors (GCTs) and treatment outcomes in recurrent GCT cases. PATIENTS AND METHODS: We retrospectively reviewed 91 patients with GCT who were treated in two tertiary Centers between 1989 and 2011. RESULTS: Eighty patients had stage I tumors, five had stage II, and six had stage III. There were 15 cases of recurrence with a median follow-up time of 58 (3-254) months. Multivariate analysis identified greater tumor size and postoperative residual tumor as independent risk factors for recurrence. Twelve patients underwent secondary surgery at first recurrence. At a median follow-up of 50 (4-185) months from first recurrence, the 5-year survival was 60% for patients with and 100% for those without residual tumor after secondary surgery, respectively (p=0.018, log-rank test). CONCLUSION: Complete cytoreduction is an important prognostic factor for recurrent cases as well as initial treatment of GCT.
AIM: To evaluate the prognostic factors of ovarian granulosa cell tumors (GCTs) and treatment outcomes in recurrent GCT cases. PATIENTS AND METHODS: We retrospectively reviewed 91 patients with GCT who were treated in two tertiary Centers between 1989 and 2011. RESULTS: Eighty patients had stage I tumors, five had stage II, and six had stage III. There were 15 cases of recurrence with a median follow-up time of 58 (3-254) months. Multivariate analysis identified greater tumor size and postoperative residual tumor as independent risk factors for recurrence. Twelve patients underwent secondary surgery at first recurrence. At a median follow-up of 50 (4-185) months from first recurrence, the 5-year survival was 60% for patients with and 100% for those without residual tumor after secondary surgery, respectively (p=0.018, log-rank test). CONCLUSION: Complete cytoreduction is an important prognostic factor for recurrent cases as well as initial treatment of GCT.
Authors: Anton Oseledchyk; Renee L Gennarelli; Mario M Leitao; Carol A Aghajanian; Alexia Iasonos; Oliver Zivanovic; Dmitriy Zamarin Journal: Cancer Med Date: 2018-04-17 Impact factor: 4.452
Authors: Peter Švajdler; Peter Vasovčák; Marián Švajdler; Monika Šedivcová; Veronika Urbán; Michal Michal; Roman Mezencev Journal: Cancers (Basel) Date: 2022-02-25 Impact factor: 6.639